Pharmacological treatment of acromegaly: Its place in the overall therapeutic approach

Journal of Neuro-Oncology

Volumn 117, Issue 3, 2014, Pages 415-420

  Korytnaya, Evgenia ^a   Barkan, Ariel ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Acromegaly; Growth hormone; IGF 1; Somatostatin

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; GROWTH HORMONE; HORMONE INHIBITOR; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR LIGAND; UNCLASSIFIED DRUG; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

ACROMEGALY; CHRONIC DISEASE; GAMMA KNIFE RADIOSURGERY; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HYPOPHYSIS FUNCTION; HYPOPHYSIS TUMOR; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; REVIEW; TRANSSPHENOIDAL HYPOPHYSECTOMY; TREATMENT INDICATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS;

ACROMEGALY; HUMANS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 84901261337     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1353-6     Document Type: Review

References (47)

1. Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25(1):102-152
2. Holdaway IM, Bolland MJ, Gamble GD (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159(2):89-95
3. Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89(2):667-674
4. Cordero RA, Barkan AL (2008) Current diagnosis of acromegaly. Rev Endocr Metab Disord 9(1):13-19
5. Bajuk Studen K, Barkan A (2008) Assessment of the magnitude of growth hormone hypersecretion in active acromegaly: reliability of different sampling models. J Clin Endocrinol Metab 93(2):491-496
6. Teale JD, Marks V (1986) The measurement of insulin-like growth factor I: clinical applications and significance. Ann Clin Biochem 23(Pt 4):413-424
7. Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ (2007) Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol 67(1):65-70
8. Claessen KM, Ramautar SR, Pereira AM et al (2013) Increased clinical symptoms of acromegalic arthropathy in patients with long-term disease control: a prospective follow-up study. Pituitary. doi:10.1007/s11102-013-0464-6
9. Damjanovic SS, Neskovic AN, Petakov MS et al (2005) Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure? Clin Endocrinol 62(4):410-417
10. Jane JA Jr, Starke RM, Elzoghby MA et al (2011) Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab 96(9):2732-2740
11. Barker FG 2nd, Klibanski A, Swearingen B (2003) Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 88(10):4709-4719
12. Castinetti F, Morange I, Dufour H, Regis J, Brue T (2009) Radiotherapy and radiosurgery in acromegaly. Pituitary 12(1):3-10
13. Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD (2007) Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin Endocrinol 67(2):310-315
14. Minniti G, Scaringi C, Enrici RM (2011) Radiation techniques for acromegaly. Radiat Oncol 6:167
15. Minniti G, Jaffrain-Rea ML, Osti M et al (2005) The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol 62(2):210-216
16. Melmed S, Colao A, Barkan A et al (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94(5):1509-1517
17. Castinetti F, Taieb D, Kuhn JM et al (2005) Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 90(8):4483-4488
18. Cozzi R, Attanasio R, Montini M et al (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 88(7):3090-3098
19. Murray RD, Melmed S (2008) A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 93(8):2957-2968
20. Melmed S, Cook D, Schopohl J, Goth MI, Lam KS, Marek J (2010) Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 13(1):18-28
21. Ayuk J, Stewart SE, Stewart PM, Sheppard MC (2004) Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin Endocrinol 60(3):375-381
22. Newman CB, Melmed S, George A et al (1998) Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 83(9):3034-3040
23. Colao A, Auriemma RS, Lombardi G, Pivonello R (2011) Resistance to somatostatin analogs in acromegaly. Endocr Rev 32(2):247-271
24. Casarini AP, Jallad RS, Pinto EM et al (2009) Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary 12(4):297-303
25. Bevan JS, Atkin SL, Atkinson AB et al (2002) Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 87(10):4554-4563
26. Bogazzi F, Colao AA, Rossi G et al (2013) Comparison of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study. Eur J Endocrinol 169(3):367-376
27. Biermasz NR, Roelfsema F, Pereira AM, Romijn JA (2009) Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly. Expert Rev Pharmacoecon Outcomes Res 9(3):223-234
28. Petersenn S, Schopohl J, Barkan A et al (2010) Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 95(6):2781-2789
29. Colao A, Ferone D, Cappabianca P et al (1997) Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 82(10):3308-3314
30. Shen M, Shou X, Wang Y et al (2010) Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocr J 57(12):1035-1044
31. Li ZQ, Quan Z, Tian HL, Cheng M (2012) Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma. J Int Med Res 40(2):517-524
32. Carlsen SM, Svartberg J, Schreiner T et al (2011) Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure. Clin Endocrinol 74(6):736-743
33. van der Lely AJ, Hutson RK, Trainer PJ et al (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358(9295):1754-1759
34. Trainer PJ, Drake WM, Katznelson L et al (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342(16):1171-1177
35. Buhk JH, Jung S, Psychogios MN et al (2010) Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J Clin Endocrinol Metab 95(2):552-558
36. Barkan AL, Burman P, Clemmons DR et al (2005) Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 90(10):5684-5691
37. Jaffe CA, Barkan AL (1992) Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 21(3):713-735
38. Sandret L, Maison P, Chanson P (2011) Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 96(5):1327-1335
39. Lafeber M, Stades AM, Valk GD, Cramer MJ, van Teding B, Zelissen PM (2010) Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur J Endocrinol 162(4):667-675
40. Cozzi R, Barausse M, Lodrini S, Lasio G, Attanasio R (2003) Estroprogestinic pill normalizes IGF-I levels in acromegalic women. J Endocrinol Invest 26(4):347-352
41. Vallette S, Serri O (2010) Oral estroprogestin: an alternative low cost therapy for women with postoperative persistent acromegaly? Pituitary 13(4):311-314
42. Cozzi R, Attanasio R, Oppizzi G et al (1997) Effects of tamoxifen on GH and IGF-I levels in acromegaly. J Endocrinol Invest 20(8):445-451
43. Dimaraki EV, Symons KV, Barkan AL (2004) Raloxifene decreases serum IGF-I in male patients with active acromegaly. Eur J Endocrinol 150(4):481-487
44. Shimon I, Barkan A (2012) Estrogen treatment for acromegaly. Pituitary 15(4):601-607
45. Jallad RS, Bronstein MD (2009) Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide. Neuroendocrinology 90(1):82-92
46. Feenstra J, de Herder WW, Haveten SM et al (2005) Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365(9471):1644-1646
47. Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der Lely AJ (2009) Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 160(4):529-533